⌘K
t
e-therapeutics plc announced it is offering shareholders virtual access to its forthcoming Annual General Meeting (AGM) via a conference call facility. The AGM is scheduled for 12:30 p.m. on 19 July 2022, and shareholders wishing to join virtually must contact investorrelations@etherapeutics.co.uk for dial-in details.
| Date | 6 Jul 2022 |
| Time | 07:00:12 |
| Category | AGMs and other meetings |
| ID | 4149R |
e-therapeutics plc
("e-therapeutics" or the "Company")
Notice to Shareholders - Annual General Meeting Virtual Access
London, UK, 6 July 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces it is offering shareholders the opportunity to attend the forthcoming AGM virtually via a conference call facility.
Shareholders that wish to join the AGM conference call, are requested to contact investorrelations@etherapeutics.co.uk for dial-in details.
The AGM will be held at 12:30p.m. on 19 July 2022 at 4 Kingdom Street, Paddington, London, W2 6BD.
Enquiries:
|
e-therapeutics plc |
|
|
Ali Mortazavi, CEO James Chandler, VP IR & Strategic Communications |
Tel: +44 (0)20 4551 8888 www.etherapeutics.co.uk |
|
|
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Broker |
|
|
Matthew Johnson/Caroline Rowe (Corporate Finance) |
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.